Ipca Laboratories Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/4zvfwnubuuojemfn26zjvfcp.pdf

Key Takeaways


Domestic Formulation

Harish Kamath: "Next 3 to 4 years, we will beat the market growth, and we should grow 1.5x market growth."

Margin Progression

Harish Kamath: "See, ideally, our intention, the margin should grow to around 18%, 18% to 20%. That is the maximum what we can achieve because they are into only generic business, and API business."

Export Formulation

Ajit Kumar: "As far as Ipca is concerned, U.S. has not made any significant overall contribution to the overall generic business."

API Business

Harish Kamath: "But now there is a stability slowly, we feel it will start slightly improving from this level. So in the current financial year... FY '26, you will see volume growth as well as price growth when it comes to the API business."

Unichem Integration


Manufacturing Expansion


Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated revenue growth8% to 10% growthFY26
Consolidated EBITDA marginImprove ~100 bps to ~20%FY26
Unichem revenue growth8% to 10% growthFY26
Unichem EBITDA marginImprove ~100 bpsFY26
Unichem medium-term revenue growth10% to 12% CAGRNext 2-3 years
Unichem medium-term margin ceiling18% to 20%Medium term
U.S. business contribution~INR100 croresFY26
U.S. product shipments~7 more products shippedFY26
U.S. filings6 to 7 products filedFY26
R&D spend~4% of stand-alone revenue (including biotech)FY26
CIS branded growth~10% growthFY26
Export formulation growth10% to 11% growthFY26
API businessVolume growth and price growthFY26
Domestic business growth vs market1.5x market growthNext 3-4 years
New plant trial productionFour greenfield plants begin trialsFY26
New plant scale-upMeaningful revenue contribution beginsFY27-FY28
U.S. business medium-term potentialINR300-400 crores (per an analyst's math, described as possible by management)3-4 years
Tariff riskGuidance given without considering tariffs; variation expected if tariffs are imposedConditional

Key Metrics

MetricQ4 FY25
Standalone revenue growth~12% overall business growth
Domestic formulation revenue growth~11% YoY for Q4; ~13.2% for full year per IQVIA
Standalone EBITDA margin21.19%, up from 18.5% in Q4 FY24, an improvement of ~2.66 ppt
Standalone EBITDA₹347 cr, up from ₹279 cr in Q4 FY24, an increase of ~24%
Consolidated EBITDA margin18.24%, up from 14.98% in Q4 FY24, an improvement of ~3.26 ppt
Consolidated EBITDA₹410 cr, up from ₹305 cr in Q4 FY24, an increase of ~35%
Consolidated revenue growth guidance (FY26)8% to 10%
Consolidated EBITDA margin guidance (FY26)~20%, up from 18.94% in FY25, an improvement of ~1 ppt
Domestic acute segment growth~10.9% vs market growth of 6.9% per IQVIA
Domestic chronic segment growth~17.9% vs market growth of ~9.8% per IQVIA
Branded formulation export growth~3% YoY for Q4; ~10% for full year
Generic formulation export growth~15% YoY for Q4, from ₹312 cr to ~₹357 cr
API business growth2% YoY for Q4; 1% for full year
Unichem revenue~₹2,211 cr for full year, growth of ~18%
Unichem EBITDA~₹265 cr for full year, up from ₹87 cr
U.S. revenue (Ipca standalone shipments)₹65 cr shipped; ~₹22-23 cr recognized on consolidated basis
U.S. revenue (Unichem)₹1,317 cr for full year, growth of ~22% vs ₹1,077 cr in FY24
R&D expenditure (standalone)~3.25% of revenue; expected to be ~4% in FY26 including biotech
South Africa generic business~₹39 cr for full year, decline of ~74% from ₹113 cr due to tender losses
Institutional business~₹355 cr for full year, growth of ~33% from ₹267 cr
MR addition (FY26)~400 planned
Capex (FY25 actual)~₹600 cr spent; FY25 plus FY26 combined ~₹1,000 cr